Inhibition of non-Ras protein farnesylation reduces in-stent restenosis

Atherosclerosis

Volumn 197, Issue 2, 2008, Pages 515-523

  Coats, Paul ^a   Kennedy, Simon ^a   Pyne, Susan ^a   Wainwright, Cherry L ^a   Wadsworth, Roger M ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Coronary disease; Coronary intervention; Restenosis; Signal transduction; Stents

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR; PROTEIN FARNESYLTRANSFERASE; PROTEIN P21; RAS PROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INTIMA; ARTICLE; ATHEROSCLEROSIS; CELL PROLIFERATION; CLINICAL ARTICLE; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RABBIT; RESTENOSIS; SMOOTH MUSCLE FIBER; STENT;

AGED; ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MUSCLE CELLS; MUSCLE, SMOOTH, VASCULAR; PHOSPHONIC ACIDS; PHOSPHORIC ACIDS; PLATELET-DERIVED GROWTH FACTOR; RABBITS;

EID: 40949145604     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.06.007     Document Type: Article

References (25)

1. Indolfi C., Avvedimento E.V., Rapacciuolo A., et al. Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo. Nat Med 1 (1995) 541-545
2. Wu C.H., Lin C.S., Hung J.S., et al. Inhibition of neointimal formation in porcine coronary artery by a Ras mutant. J Surg Res 99 (2001) 100-106
3. Ehrhardt A., Ehrhardt G.R.A., Guo X., and Schrader J.W. Ras and relatives-job sharing and networking keep an old family together. Exp Hematol 30 (2002) 1089-1106
4. Lane K.T., and Beese L.S. Structural biology of protein farnesyltransferase and geranylgeranlytransferase type 1. J Lipid Res 47 (2006) 681-699
5. Basso A.D., Mirza A., Liu G., et al. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTor signalling. J Biol Chem 280 (2005) 31101-31108
6. Hussein D., and Taylor S.S. Farnesylation of Cenp-F is required for G2/M progression and degradation after mitosis. J Cell Sci 115 (2002) 3403-3414
7. Basso A.D., Kirschmeier P., and Bishop W.R. Farnesyl transferase inhibitors. J Lipid Res 47 (2006) 15-31
8. Work L.M., McPhaden A.R., Pyne N.J., et al. Short-term local delivery of an inhibitor of Ras farnesyltransferase prevents neointima formation in vivo after porcine coronary balloon angioplasty. Circulation 104 (2001) 1538-1543
9. Chemla E., Castier Y., Julia P., et al. Inhibition of intimal hyperplasia by an antisense oligonucleotide if farnesyl transferase delivered endoluminally during iliac angioplasty in a rabbit model. Ann Vasc Surg 11 (1997) 581-587
10. Crul M., de Klerk G.J., Beijnen J.H., and Schellens J.H.M. Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs 12 (2001) 163-184
11. Manne V., Ricca C.S., Brown J.G., et al. Ras farnesylation as a target for novel antitumor agents: potent and selective farnesyl diphosphate analog inhibitors of farnesyltransferase. Drug Dev Res 34 (1995) 121-137
12. Flaherty J.D., and Davidson C.J. Diabetes and coronary revascularisation. JAMA 293 (2005) 1501-1508
13. Togni M., Windecker S., Cocchia R., et al. Sirolimus-eluting stents associated with paradoxic coronaray vasoconstriction. J Am Coll Cardiol 46 (2005) 231-236
14. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors and outcomes of thrombosis after successful implantation of drug-eluting stents. JAMA 293 (2005) 2126-2130
15. Schwartz R.S., and Edelman E.R. Drug-eluting stents in preclinical studies: recommended evaluation from a Consensus Group. Circulation 106 (2002) 1867-1873
16. Sambi B.S., Hains M.D., Waters C.M., et al. The effect of RGS12 on PDGFbeta receptor signalling to p42/p44 mitogen activated protein kinase in mammalian cells. Cell Signal 18 (2006) 971-981
17. Kennedy S., McPhaden A.R., Wadsworth R.M., and Wainwright C.L. Correlation of leukocyte adhesiveness, adhesion molecule expression and leukocyte-induced contraction following balloon angioplasty. Br J Pharmacol 130 (2000) 95-108
18. Van Belle E., Maillard L., Tio F.O., and Isner J.M. Accelerated endothelialization by local delivery of recombinant human vascular endothelial growth factor reduces in-stent intimal formation. Biochem Biophys Res Commun 235 (1997) 311-316
19. Malik N., Gunn J., Holt C.M., et al. Intravascular stents: a new technique for tissue processing for histology, immunohistochemistry, and transmission electron microscopy. Heart 80 (1998) 509-516
20. Gunn J., Arnold N., Chan K.H., et al. Coronary artery stretch versus deep injury in the development of in-stent neointima. Heart 88 (2002) 401-405
21. Kennedy S., Wadsworth R.M., and Wainwright C.L. Effect of antiprolifetative agents on vascular function in normal and in vitro balloon injured porcine coronary arteries. Eur J Pharmacol 481 (2003) 101-107
22. End D.W., Smets G., Todd A.V., et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61 (2001) 131-137
23. Vojtek A.B., and Der C.J. Increasing complexity of the Ras signaling pathway. J Biol Chem 273 (1998) 19925-19928
24. Miller A.M., McPhaden A.R., Wadsworth R.M., and Wainwright C.L. Inhibition by leukocyte depletion of neointima formation after balloon angioplasty in a rabbit model of restenosis. Cardiovasc Res 49 (2001) 838-850
25. Cuda G., Paterno R., Ceravolo R., et al. Protection of human endothelial cells from oxidative stress-role of Rasd-ERK1/2 signalling. Circulation 105 (2002) 968-974